360 related articles for article (PubMed ID: 27703030)
21. Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression.
Umemura S; Sowa Y; Iizumi Y; Kitawaki J; Sakai T
Cancer Sci; 2020 Jun; 111(6):2052-2061. PubMed ID: 32291856
[TBL] [Abstract][Full Text] [Related]
22. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
Sensi M; Catani M; Castellano G; Nicolini G; Alciato F; Tragni G; De Santis G; Bersani I; Avanzi G; Tomassetti A; Canevari S; Anichini A
J Invest Dermatol; 2011 Dec; 131(12):2448-57. PubMed ID: 21796150
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
Palisoul ML; Quinn JM; Schepers E; Hagemann IS; Guo L; Reger K; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2017 Dec; 16(12):2881-2891. PubMed ID: 28904132
[TBL] [Abstract][Full Text] [Related]
24. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
26. AXL regulates mesothelioma proliferation and invasiveness.
Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
[TBL] [Abstract][Full Text] [Related]
27. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
[TBL] [Abstract][Full Text] [Related]
28. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A
Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564
[TBL] [Abstract][Full Text] [Related]
29. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
[TBL] [Abstract][Full Text] [Related]
30. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
[TBL] [Abstract][Full Text] [Related]
31. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
[TBL] [Abstract][Full Text] [Related]
33. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
34. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
[TBL] [Abstract][Full Text] [Related]
35. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction.
Landolt L; Furriol J; Babickova J; Ahmed L; Eikrem Ø; Skogstrand T; Scherer A; Suliman S; Leh S; Lorens JB; Gausdal G; Marti HP; Osman T
Physiol Rep; 2019 May; 7(10):e14091. PubMed ID: 31134766
[TBL] [Abstract][Full Text] [Related]
36. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
[TBL] [Abstract][Full Text] [Related]
37. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells.
Cheng P; Phillips E; Kim SH; Taylor D; Hielscher T; Puccio L; Hjelmeland AB; Lichter P; Nakano I; Goidts V
Stem Cell Reports; 2015 May; 4(5):899-913. PubMed ID: 25921812
[TBL] [Abstract][Full Text] [Related]
38. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.
Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
Sci Rep; 2017 Sep; 7(1):10613. PubMed ID: 28878389
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
Xu F; Li H; Sun Y
Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
[TBL] [Abstract][Full Text] [Related]
40. In Situ Nanofiber Formation Blocks AXL and GAS6 Binding to Suppress Ovarian Cancer Development.
Yin H; Hua Y; Feng S; Xu Y; Ding Y; Liu S; Chen D; Du F; Liang G; Zhan W; Shen Y
Adv Mater; 2024 May; 36(21):e2308504. PubMed ID: 38546279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]